Press Releases

Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Aster Insights, a bioinformatics company with the most advanced, direct-patient, lifetime-consented clinicogenomics data to accelerate oncology discovery research, today announced the availability of the AsterExome panel, which can simultaneously enable whole exome sequencing (WES) with additional coverage for target regions known to contain

Daewoong Pharmaceutical (CEO Jeon Sengho and Lee Chang-jae) announced today that it had signed a Global License Agreement for its autoimmune disease drug candidate DWP213388 with Vitalli Bio, a US biotechnology company, on April 28. With this agreement, Daewoong Pharmaceutical will grant exclusive rights for the development and commercialization of DWP213388 in the global market to Vitalli Bio, a portfolio company of Aditum Bio. Daewoong Pharmaceutical will retain rights in some Asi

Amicus Therapeutics announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending marketing authorization of miglustat, the enzyme stabilizer component of AT-GAA. A decision for miglustat from the European Commission (EC) is expected in the third quarter of 2023, after which the two-component therapy will be fully approved, and the Company will begin the country-by-country reimbursement and launch proces

Mainz Biomed NV, a molecular genetics diagnostic company specializing in the early detection of cancer, announced that it has added the Instituto de Microecologia in Madrid to its growing network of lab partners across Europe and in select international markets. ColoAlert®, Mainz Biomed’s flagship product, is a highly efficacious and easy-to-use, at-home detection test for colorectal cancer (CRC). For more than 60 years, the Instituto de Microecologia has been a pioneer in microbiot

Nippon Express Ltd. a group company of NIPPON EXPRESS HOLDINGS, INC., has been awarded IATA CEIV Pharma certification*, a quality certificate for pharmaceutical transport established by the International Air Transport Association (IATA), for its facility in the suburbs of Heathrow Airport, effective February 28 this year. Logo: https://kyodonewsprwire.jp/img/202304184992-O1-JHM4p34o Photo: Interior of facility that has obtained CEIV Pharma certification https://cdn.

Zapata Computing, a leading developer of Quantum AI software for enterprises, today announced that it has signed an agreement with the prestigious Technical University of Denmark (DTU) to research how quantum can create near-term value for pharmaceutical manufacturers. The initiative is slated to kick-off later in 2023 and will explore real-world commercial applications and use cases in life sciences that can help set the foundation for solving larger pharmaceutical manufacturing challenges u

MaaT Pharma a late-stage biotechnology company, leader in the development of dedicated Microbiome Ecosystem Therapies TM  1 to improve the survival of cancer patients, announces today that the Food and Drug Administration  has lifted the clinical hold and authorized the Investigational New Drug application (“IND”),submitted by the Company to initiate a single-arm, open-label, pivotal Phase 3 clinical trial in the United States evaluating the safety and efficacy of MaaT01

Everest Medicines  a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today that Nefecon, the first-in-disease treatment for primary immunoglobulin A nephropathy (IgAN), has been approved by the Hainan Medical Products Administration for clinical use in Shanghai Ruijin Hospital's Hainan subsidiary. The launch of this early-access program in Hainan marks the beginning of a new treatment era for Ig

Speaking at CPHI Japan 2023 (19-21), one keynote speaker – Ian Haydock, Editor-In-Chief, Insights, Asia-Pacific at Citeline – predicted that the continued rise of biopharma innovation in China is the big macro trend in the APAC region that could potentially lead to shifts in outsourcing and manufacturing strategies regionally. “Historically, we have seen a dual strategy of focusing on China and the US for emerging innovators in China. However, a series of recent se

Aquestive Therapeutics, Inc., a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today announced the U.S. Food and Drug Administration (FDA) has conditionally accepted the proprietary name Anaphylm™ as the proposed brand name for AQST-109, the Company’s polymer matrix-based epinephrine prodrug administered as a sublingual film in development for the treatment of s